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ABSTRACT
Introduction: DNA repair is a double-edged sword in lung carcinogenesis. 
When defective, it promotes genetic instability and accumulated genetic alterations. 
Conversely these defects could sensitize cancer cells to therapeutic agents inducing 
DNA breaks.
Methods: We used immunohistochemistry (IHC) to assess MSH2, XRCC5, and 
BRCA1 expression in 443 post-chemotherapy specimens from patients randomized 
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INTRODUCTION
Non-small cell lung cancers (NSCLC) account for 
approximately 85% of lung cancers. Despite curative-
intent surgical resection, 20% of Stage I NSCLC patients 
die within 5 years, even following adjuvant chemotherapy, 
as NSCLC is highly metastatic and frequently chemo-
resistant [1]. However, complete tumor resection followed 
by adjuvant platinum-based chemotherapy plays a central 
role as a curative treatment for NSCLC. The benefit 
offered by adjuvant chemotherapy is modest, with an 
absolute improvement in 5-year overall survival (OS) 
ranging from 4 to 15% [2-4]. The French Cooperative 
Thoracic Intergroup (IFCT) initiated a large Phase 3 trial in 
2001 to evaluate i) tolerance and efficacy of gemcitabine-
cisplatin versus paclitaxel-carboplatin perioperative 
chemotherapies; ii) the potential prognostic molecular 
biomarkers that could be helpful in defining therapeutic 
options and identifying genes/pathways that could be 
therapeutically targeted [5]. Lethal cisplatin-induced cell 
injury was extensively studied in vitro: cisplatin binds 
to DNA and induces adducts by covalent cross-linking 
between DNA strands, thereby inhibiting DNA replication 
and leading to cell apoptosis. Nevertheless, DNA repair 
mechanisms that reduce the effectiveness of cisplatin can 
ensure tumor-cell survival. The way to overcome this 
resistance is to combine cisplatin with a molecule inducing 
cell toxicity through alternative mechanisms, such as 
gemcitabine (2′,2′-difluoro-2′-deoxycytidine), a nucleoside 
analogue, which interferes with DNA synthesis, or 
paclitaxel, a tubulin depolymerization-inhibitor, which 
alters the mitotic spindle by stabilizing microtubules. 
Combination platinum-based chemotherapy achieves 30-
40% 1-year survival rates in Stage IV NSCLC and has 
proven superior to single agents or best supportive care in 
this setting. Gemcitabine inhibits the repair of cisplatin-
induced intrastrand adducts and interstrand cross-links [6]. 
Paclitaxel, by preventing microtubule depolymerisation, 
blocks the cell cycle progression in late G2-M phases. 
It has also been proposed that taxanes (docetaxel and 
paclitaxel) can induce DNA single-strand breaks (SSB), 
depending on the cell type [7,8]. The DNA damage repair 
process has crucial implications and, depending on their 
DNA repair efficiency, cancer cells can: i) interrupt the cell 
cycle to repair the DNA damage, ii) commence apoptosis, 
or iii) proceed with mitosis and cell proliferation without 
repairing the damage (while more molecular alterations 
accumulate). While the TP53 gene product has been 
shown as a key guardian of genome integrity [9], specific 
enzymes involved in genome integrity survey or DNA 
damage repair have been described, including key DNA-
repair proteins such as XRCC5, MSH2, BRCA1, and 
O6MGMT, respectively involved in nucleotide excision 
repair (NER), base excision repair (BER), mismatch repair 
(MMR), or non-homologous end-joining (NHEJ) systems. 
These enzymes have been previously studied individually 
in NSCLC patients to assess their prognostic or predictive 
roles [10-23]. In response to the lack of consensus in the 
literature regarding the value of these enzymes’ expression 
in tumors as predictive biomarkers in NSCLC [24], the 
IFCT 0002 Phase 3 randomized trial, with its large patient 
sample (528 patients enrolled between 2001 and 2005) and 
the homogeneity of their treatments, constituted further 
opportunity to assess whether or not XRCC5, MSH2, 
BRCA1, and O6MGMT represent reliable biomarkers in 
Stage I and II NSCLC patients, treated with taxane- or 
anti-metabolite-based perioperative chemotherapy.
in a Phase 3 trial, comparing two neoadjuvant regimens in 528 Stage I-II non-small 
cell lung cancer (NSCLC) patients (IFCT-0002). O6MGMT promoter gene methylation 
was analyzed in a subset of 208 patients of the same trial with available snap-frozen 
specimens.
Results: Median follow-up was from 90 months onwards. Only high BRCA1 (n = 
221, hazard ratio [HR] = 1.58, 95% confidence interval [CI] [1.07-2.34], p = 0.02) 
and low MSH2 expression (n = 356, HR = 1.52, 95% CI [1.11-2.08], p = 0.008) 
significantly predicted better overall survival (OS) in univariate and multivariate 
analysis. A bootstrap re-sampling strategy distinguished three patient groups at high 
(n = 55, low BRCA1 and high MSH2, median OS >96 months, HR = 2.5, 95% CI [1.45-
4.33], p = 0.001), intermediate (n = 82, median OS = 73.4 p = 0.0596), and low (high 
BRCA1 and low MSH2, n = 67, median OS = ND, HR = 0.51, 95% CI [0.31-0.83], p = 
0.006) risk of death.
Interpretation: DNA repair protein expression assessment identified three 
different groups of risk of death in early-stage lung cancer patients, according to 
their tumor MSH2 and BRCA1 expression levels. These results deserve prospective 
evaluation of MSH2/BRCA1 theranostic value in lung cancer patients treated with 
combinations of DNA-damaging chemotherapy and drugs targeting DNA repair, such 
as Poly(ADP-ribose) polymerase (PARP) inhibitors.
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RESULTS
DNA repair protein alterations and patient 
characteristics
MSH2, XRCC5, and BRCA1 tumor immunostaining 
assays were technically possible for 356 (77.2%), 396 
(85.9%), and 221 (47.9%) patients with no complete 
histological response, respectively (Figure 1), revealing 
specific nuclear staining on a slide containing substantial 
tumor content, without extensive necrosis (Figure 2). 
Staining intensity varied markedly between lung-cancer 
samples and within the same slide, with strongly-stained 
clusters of tumor cells sometimes observed adjacent to 
weakly-stained tumor cells. 
The characteristics of the IFCT-002 subset patients 
with IHC analyses have previously been described [25] , 
presenting a mean age of 60.0 years (SD: 9.1, range: 35-76 
years) and Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of 0 (77.2-77.8%). Only 9.7 to 
10.2% of patients were “light” smokers (<10 packs per 
year), and 51.1 to 56.3% had non-squamous histology. 
The 396 patients with at least one DNA repair protein 
analysis available exhibited higher probability of having 
non-squamous NSCLC (p <0.0001), though no significant 
difference was observed with the 132 patients without 
Figure 1: Patients and histological sample disposition in the Bio-IFCT 0002 study.
Oncotarget4316www.impactjournals.com/oncotarget
DNA-repair protein IHC analyses for other characteristics. 
They especially exhibited similar OS and DFS values [25] 
. Of the 208 snap-frozen specimens, O6MGMT promoter 
methylation was found in 14.9%, and this subset was also 
characterized by a higher frequency of non-squamous 
histology (46.2% vs. 32.8%, p = 0.0051) in comparison 
with the rest of the population [26].
O6MGMT methylation and XRCC5 expression do 
not influence survival
The average XRCC5 expression intensity score 
was 25.07 ± 25.35, with a median of 20 [10-30]. 
Neither O6MGMT methylation, nor XRCC5 expression 
either dichotomized at the median value or studied as 
a continuous variable, had any impact on OS and DFS 
of early-stage NSCLC patients in Cox models (data not 
shown).
Figure 2: Representative intensity of BRCA1, MSH2, and XRCC5 immunostaining in non-small cell lung cancer, 
demonstrating negative (I = 0), weak (I = 1), moderate (I = 2), or strong (I = 3) staining.
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High MSH2 expression significantly predicts 
worse overall survival
The average MSH2 expression intensity score was 
231.03 ± 69.09, with a median of 255 [180-300]. MSH2 
staining was first studied as a continuous variable. Low 
MSH2 staining was more frequent in young (p = 0.03) and 
ECOG PS 0 patients (p = 0.008) (Table 1). MSH2 status 
did not significantly differ according to gender, treatment 
arm, number of chemotherapy cycles, histological 
differentiation, pathological stage, smoking status, or 
clinical T. MSH2 staining, analyzed as a continuous 
variable, and tested for a 1 unit increase of IHC score 
(from 0 to 300), significantly predicted OS in univariate 
analysis (HR = 1.003, 95% CI [1.000-1.005]; p = 0.020) 
and multivariate backward model (adjusted HR = 1.003, 
95% CI [1.000-1.005]; p = 0.03), including all variables 
with a p-value <0.2 in the univariate analysis (gender, 
Stage I vs. II, and squamous vs. non-squamous histology) 
(Table 2).
Subsequent statistical analyses, correlating MSH2 
expression with DFS or OS, have dichotomized the MSH2 
score, with low (score below the median of 255, n = 167 
[46.9%]) and high MSH2 expression (score above the 
median, n = 189 [53.1%]). Patients whose tumor samples 
expressed low MSH2 had not reached the median OS at 
the time of follow-up, compared to patients whose tumor 
samples expressed high MSH2 (60.5 months [44.6-77.8]) 
(Figure 3, left panel), in both univariate (HR = 0.65 [0.48 
to 0.89], log-rank p = 0.007) and multivariate analysis 
(Cox model, including stage, histology, and gender, 
adjusted HR = 0.66, 95% CI [0.48-0.90], p = 0.008) 
(Table 2). DFS was not significantly affected according to 
MSH2 level (Table 2 and Figure 3, right panel). Finally, 
MSH2 influence on prognosis did not differ according 
Table 1: MSH2/BRCA1 Immunostaining Characteristics
Characteristics MSH2 < Q2n = 167
MSH2 ≥ Q2
n = 189 p
BRCA1 < Q2
n = 92
BRCA1 ≥ Q2
n = 129 p
MSH2 < Q2 +
BRCA1 ≥ Q2
n = 67
Other
n = 137
p
Gender
 Male 129 (77.2%) 152 (80.4%) 0.4631 72 (78.3%) 98 (76%) 0.6901 48 (71.6%) 106 (77.4%) 0.3715
 Female 38 (22.8%) 37 (19.6%) 20 (21.7%) 31 (24%) 19 (28.4%) 31 (22.6%)
Age at inclusion
 ≤60 years old
 >60 years old
91 (54.5%)
76 (45.5%)
77 (40.7%)
112 (59.3%)
0.0095 42 (45.7%)
50 (54.3%)
68 (52.7%)
61 (47.3%)
0.3007 38 (56.7%)
29 (43.3%)
64 (46.7%)
73 (53.3%)
0.1796
Pack-year *
 ≤10
 >10
19 (11.4%)
147 (88.6%)
17 (9.1%)
170 (90.1%)
0.4656 9 (9.9%)
82 (90.1%)
12 (9.5%)
115 (90.5%)
0.9133 9 (13.6%)
57 (86.4%)
11 (8.1%)
125 (91.9%)
0.2156
Performance status
 0 139 (83.2%) 136 (72%) 0.0113 67 (72.8%) 105 (81.4%) 0.1306 57 (85.1%) 99 (72.3%) 0.0428
 1 or 2 28 (16.8%) 53 (28%) 25 (27.2%) 24 (18.6%) 10 (14.9%) 38 (27.7%)
Histology
 SCC 58 (34.7%) 82 (43.4%) 0.0952 31 (33.7%) 50 (38.8%) 0.4412 23 (34.3%) 55 (40.1%) 0.4220
 Non-SCC 109 (65.3%) 107 (56.6%) 61 (66.3%) 79 (61.2%) 44 (65.7%) 82 (59.9%)
Arm (ITT)
 gemcitabine 4 cycles PRE 41 (24.5%) 47 (24.9%)
0.1944
17 (18.5%) 33 (25.6%)
0.5934
18 (26.9%) 28 (20.4%)
0.746
 gemcitabine 2 cycles PERI 35 (21.0%) 51 (27.0%) 23 (25.0%) 33 (25.6%) 15 (22.4%) 37 (27.0%)
 paclitaxel 4 cycles PRE 38 (22.8%) 49 (25.9%) 25 (27.2%) 32 (24.8%) 17 (25.4%) 36 (26.3%)
 paclitaxel 2 cycles PERI 53 (31.7%) 42 (22.2%) 27 (29.3%) 31 (24.0%) 17 (25.4%) 36 (26.3%)
Number of cycles received
 ≤2 99 (59.3%) 106 (56.1%) 0.5425 53 (57.6%) 68 (52.7%) 0.4711 37 (55.2%) 75 (54.7%) 0.9485
 >2 68 (40.7%) 83 (43.9%) 39 (42.4%) 61 (47.3%) 30 (44.8%) 62 (45.3%)
Stage
 0,I 91 (54.5%) 106 (56.1%) 0.7628 41 (44.6%) 73 (56.6%) 0.0779 40 (59.7%) 64 (46.7%) 0.0814
 II, III, IV 76 (45.5%) 83 (43.9%) 51 (55.4%) 56 (43.4%) 27 (40.3%) 73 (53.3%)
cT
 T1 112 (67.1%) 116 (61.4%) 0.2642 60 (65.2%) 82 (63.6%) 0.8006 45 (67.2%) 83 (60.6%) 0.3613
 T2 ou T3 55 (32.9%) 73 (38.6%) 32 (34.8%) 47 (36.4%) 22 (32.8%) 54 (39.4%)
*information missing for 3 patients
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to treatment arm (paclitaxel versus gemcitabine), since 
no significant interaction was observed between MSH2 
expression status and treatment arm for DFS prediction 
(data not shown). For external validation of our data, 
we used kpm.plot.com online software, computing the 
MSH2 mRNA prognostic analyses in 681 Stage I-to-III 
patients, with gene-expression data and OS information 
downloaded from the GEO (Affymetrix microarrays only), 
EGA, and TCGA databases (2015 database release) [27]. 
OS analysis was dichotomized according to the median 
value (Figure 4) and revealed high MSH2 mRNA content 
to also be significantly associated with poorer survival in 
this series of patients (HR = 1.72; 95% CI [1.39-2.12], p 
= 3.8x10-7).
Table 2: MSH2 Expression, Progression-Free Survival, and Overall Survival in Patients from the Bio-IFCT 0002 Trial
Outcome MSH2 < Q2n =167
MSH2 ≥ 
Q2
n =189
p BRCA1 < Q2n =92
BRCA1 ≥ Q2
n =129 p
MSH2 < Q2 +
BRCA1 ≥ Q2
n =67
Other
n = 137
p
PFS Number of events 97 120 92 69 32 86
Median (month) 36.1 [24.1-61.1] 35.4 [23.2-46.4] 16.2 [13.3-36.0] 54.2 [39.8-ND]
ND 32.5 [16.0-
49.1]
HR (95% CI) 0.88 [0.67-1.14] 1 0.33 1.44 [1.01-2.04] 1 0.04
0.62 [0.42-
0.94] 1 0.02
Adj. HR‡ (95% CI) - - - - - - 0.63 [0.42-0.95] 1 0.03
OS Number of events 66 102 49 51 21 70
Median (month) ND 60.5 [44.6-77.8] 47.1 [28.1-ND] 90.6 [73.5-ND]
ND 66.5 [42.3-
ND]
HR (95% CI) 0.65 [0.48-0.89] 1 0.007 1.58 [1.07-2.34] 1 0.02 0.50 [0.31-0.82] 1 0.006
Adj. HR‡ (95% CI) 0.66 [0.48-0.90] 1 0.008 1.58 [1.07- 2.34] 1 0.02
0.51 [0.31-
0.83] 1 0.006
‡ HR was adjusted according to histology, stage, and gender for OS; HR was adjusted according to histology and stage for 
PFS.
Figure 3: MSH2 level impact on both overall survival (A) and progression-free (B) survival rates. A. Overall survival 
curve for the 356 patients in the bio-IFCT 0002 trial, according to MSH2 expression. B. Progression-free survival rate curve for the 356 
patients in the bio-IFCT 0002 trial, according to MSH2 expression.
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MSH2 expression is not altered by chemotherapy
Given that patient tumor samples were collected 
following neoadjuvant chemotherapy, and since we were 
not able to compare such samples with the diagnostic 
biopsies obtained before surgery, we raised the question 
of chemotherapy’s influence on MSH2 expression. We 
used cell lines reproducing the most frequent molecular 
alterations in NSCLC: H1299 (p53 deletion, RASSF1A 
methylation), H1650 (EGF-R mutation, RASSF1A 
methylation, p53 mutation, CDKN2A deletion), H1975 
(EGF-R mutation, p53 mutation, R273H, PI3K mutation, 
CDKN2A deletion), and A549 (RASSF1A methylation, 
RasSer12, CDKN2A deletion, Lkb1/STK11 mutation). 
We also used two isogenic non-tumorigenic, immortalized, 
bronchial cells lines with a low number of molecular 
alterations (CDK4 and hTERT lentiviral-mediated 
overexpression), HBEC-3 (p16/Rb block), and HBEC-
3RasV12 (p16/Rb block, Ras mutation).
Table 3: Sequence of Primers Used for PCR
Gene name Primer sequence (5’-3’)
BRCA1 Forward: ACAGCTGTGTGGTGCTTCTGTGReverse: CATTGTCCTCTGTCCAGGCATC
MSH2 Forward: GGAGGAGAGACTGCTGGAGAReverse: TCCCTTTTTGCCTTTCAACA
XRCC5 Forward: GAAGGTGAAGATGGGTTGGAReverse: AATTGGAGCCAATGGTCAGT
S16 Forward: CTGGAGCCAGTTCTGCTTCTReverse: TCTGGTAATAGGCCACCAGG
Figure 4: Kaplan-Meier overall survival curves according to MSH2 mRNA, from GEO (Affymetrix microarrays 
only), EGA, and TCGA databases (2015 database release), using kpm.plot.com online software, in 681 NSCLC Stage 
I-III patients.
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In line with the clinical trial findings (i.e., high 
MSH2 expression correlating with poor OS), we found that 
the cell lines expressing the highest MSH2 mRNA basal 
content were the H1299 and A549 cell lines (Figure 5), 
namely those with the highest tumorigenic potential when 
xenografted in nude mice [28-30]. Cells were incubated 
in the presence of cisplatin/gemcitabine or cisplatin/
paclitaxel, as detailed in Materials and Methods. Treatment 
efficacy was evaluated by measuring DNA fragmentation 
and immunolabeling cytochrome C as readouts for cell 
apoptosis. In the HBEC-3 non-tumorigenic cell line, both 
cisplatin/paclitaxel and cisplatin/gemcitabine treatments 
significantly increased DNA fragmentation 2.5- to 2.8-
fold (Figure 6A, t-test, treated cells vs. control cells, p 
<0.05), as in the HBEC-3-RasV12, A549, H1650, and 
H1299 cells (data not shown). Both treatments increased 
cytochrome c cytoplasmic signal nearly 2-fold in these 
cells (Figure 6B), again demonstrating chemotherapy-
induced apoptosis in such conditions in non-tumorigenic 
and tumorigenic cell lines. Conversely, chemotherapy 
had no impact on MSH2 protein content, as demonstrated 
by the stable MSH2/actin ratios (Figure 6C). It has been 
suggested that such chemotherapy regimens could induce 
p38/Mitogen-Activated Protein Kina se14 (MAPK14) 
activity, a stress-activated signaling, which contributes to 
the cytotoxic effect of cisplatin [31-33]. Here, we reported 
that, despite the observed phospho-p38 increase (as a 
readout for p38 activation) induced by cisplatin (shown 
here for A549 cells in Figure 7), the MSH2 protein levels 
were not altered by chemotherapy (Figures 6C and 7) in 
HBEC-3 (non-tumorigenic), H1650 (EGFR mutation), and 
A549 (K-Ras mutation) cell lines, as with H1299 cell lines 
(data not shown). In the A549 cells, blocking p38 MAPK 
activation using pharmacological inhibitor SB202190 did 
not modify MSH2 expression, while A549 cells contained 
an inactivating STK11/LkB1 mutation, with Lkb1 
inactivation leading to p38 hyper-activation [34] .These 
in vitro results suggest that neo-adjuvant chemotherapy 
did not alter MSH2 expression, and that MSH2 status was 
independent of p38 activity in tumors from patients of the 
Bio-IFCT0002 trial. In line with this data, we did not find 
that phospho-p38 intensity staining had any influence on 
OS and DFS of patients from the Bio-IFCT0002 trial, nor 
did treatment arm (data not shown). 
A new signature for high-risk recurrence and 
death
BRCA1 is another extensively studied DNA-repair 
protein. Allelic loss, mutations, and gene methylation 
have been shown to alter BRCA1 protein content. We 
also report that low BRCA1 expression significantly 
predicted both worse OS and PFS in early-stage NSCLC. 
Figure 5: MSH2 mRNA expression level in lung cancer cell lines. The different letters above the histograms represent the 
significant differences between them (one-way ANOVA, following post-hoc test of Fisher’s LSD, p <0.05).
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Figure 6: Effects of cisplatin/paclitaxel or cisplatin/gemcitabine treatment on DNA fragmentation (A), cytochrome 
C release (B), and MSH2 expression (C) in bronchial cell lines. At 50% confluence, the bronchial cell lines were incubated or 
not (control) with cisplatin (2µM) for 3h before incubation for 48h with paclitaxel (10nM) or gemcitabine (250nM). Following treatment, 
DNA fragmentation, cytochrome C release, and MSH2 levels were measured. Results were expressed in base 100, with 100 attributed to 
the control cells (n = 3, t-test vs. control cells, *p <0.05).
Oncotarget4322www.impactjournals.com/oncotarget
The average BRCA1 expression intensity score was 
103.98 ± 74.07, with a median of 100 [30-160]. As with 
MSH2, BRCA1 status was not significantly affected by the 
clinical parameters, either when low or high according to 
dichotomization at median value (Table 1). 
To assess the influence of BRCA1 expression on 
DFS and OS, expression IHC scores were dichotomized 
at median value, with low score defined as below the 
median value of 100 (92 [41.6%] patients) and high score 
as above (129 [58.4%] patients). BRCA1 low H-score 
predicted worse OS in our Cox model adjusted for 
variables significantly affecting OS (adjusted HR = 1.58 
95% CI [1.07-2.34], p = 0.02) while leading to worse DFS 
(HR = 1.44 95% CI [1.01-2.04], p = 0.04), though not 
in a Cox model adjusted for histology and stage (Table 
2 and Figure 8, A and B left panel, respectively). No 
significant interaction between BRCA1 expression status 
and treatment arm was observed for DFS or OS prediction 
(data not shown).
In our experiments, the 8F7 clone did not enable 
reliable western blot (WB) analyses in lung cancer cell 
line extracts, despite claims that it functions for WB 
application. We then checked for any chemotherapy 
effects on cells in BRCA1 mRNA species, as measured 
by semi-quantitative qRT-PCR. We found only a slight 
increase in BRCA1 mRNA in non-tumorigenic cells 
following treatment by both doublets in HBEC-3 cells, 
potentiated by p38 inhibition, and only after paclitaxel-
based doublet exposure in HBEC-3-RasV12 cells (Figure 
9). In lung cancer cells, there was no variation (A549) 
or a slight decrease (H1975, H1650, H1299) of BRCA1 
mRNA upon chemotherapy doublet treatment, with no 
potentiation by the p38 inhibitor (Figure 9). 
Taking into account both the MSH2 and BRCA1 
analyses, we subsequently tried to establish whether a 
combined expression signature of these two DNA repair 
proteins influenced the outcome of patients from the 
Bio-IFCT0002 trial. Among the 396 specimens, BRCA1 
and MSH2 were simultaneously available in 204. Low 
MSH2 combined with high BRCA1 expression was more 
frequent in low-ECOG PS patients (p = 0.04) (Table 1). 
The proportion of low MSH2 cases was 50% (55 cases out 
of 110) in the low BRCA1 group, and 50% (55 cases out 
of 110) in the high BRCA1 group. 
Figure 7: MSH2 expression following p38 blocking or cisplatin/paclitaxel or cisplatin/gemcitabine treatment in A549 
cells. At 50% confluence, bronchial cell lines were incubated or not (control) for 1h with SB202190 (20µM) then with cisplatin (2µM) for 
3h before incubation for 48h with paclitaxel (10nM) or gemcitabine (250nM). Following treatment, MSH2 and phospho-p38 levels were 
measured by WB. Results were expressed in base 100, with 100 attributed to the control cells, i.e., A549 without any treatment (one-way 
ANOVA, following post-hoc test of Fisher’s LSD, **: p <0.01, NS: non-significant).
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Figure 8: BRCA1 level impact on both overall survival (A) and progression-free (B) survival rates in combination with 
MSH2 level or alone. A. Overall survival curve for the 221 patients in the bio-IFCT 0002 trial, according to BRCA1 with or without 
MSH2 expression. B. Progression-free survival rate curve for the 221 patients in the bio-IFCT 0002 trial, according to BRCA1 with or 
without MSH2 expression. C. Identification of three groups of early-lung cancer patients from low to high risk of recurrence, according to 
BRCA1 and MSH2 level. “High” risk of death: low BRCA1/ high MSH2 (n = 55); “low”: high BRCA1/low MSH2 (n = 67); “intermediate” 
for other combinations (n = 82).
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In both univariate and multivariate analysis, 
Cox models showed that high BRCA1 and low MSH2 
expression appears to predict longer OS (HR = 0.51 
[0.31-0.83], p = 0.006) and DFS (HR = 0.63 [0.42-0.95], 
p = 0.03), adjusted for clinical variables significantly 
influencing OS (histology, pathological stage, and gender) 
or DFS (histology and pathological stage), respectively 
(Table 2) (Figure 8, A and B right panel, respectively). A 
prognostic score was then constructed according to Cox 
models and validated by a bootstrap re-sampling strategy, 
which accurately defined three groups of early-lung 
cancer patients at low to high risk of recurrence and death 
despite perioperative cisplatin-based chemotherapy. These 
three patient groups were at “high risk” of death when 
Figure 9: BRCA1 mRNA expression following p38 blocking or cisplatin/paclitaxel or cisplatin/gemcitabine treatment, 
in immortalized lung or lung cancer cell lines. At 50% confluence, cell lines were incubated or not (control) for 1h with SB202190 
(20µM) then with cisplatin (2µM) for 3h before incubation for 48h with paclitaxel (10nM) or gemcitabine (250nM). Following treatment, 
BRCA1 mRNA expression was assayed by qRT-PCR. Results were expressed in base 100, with 100 attributed to the control cells, i.e., cells 
without any treatment for each cell line (one-way ANOVA, following post-hoc test of Fisher’s LSD, **: p <0.01, NS: non-significant).
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BRCA1 was low and MSH2 high (n = 55, median OS 
>96 months, HR = 2.5, 95% CI [1.45-4.33], p = 0.001), 
at “low risk” when BRCA1 was high and MSH2 low (n 
= 67, median OS = 36.8 months ND, HR = 0.512.5, 95% 
CI [0.31-0.83], p = 0.006), and at “intermediate risk” in 
other combinations (n = 82, median OS = 73.4 p = 0.0596) 
(Figure 8C). 
Finally, no significant interaction between low 
BRCA1 and high MSH2 expression status and treatment 
arm was observed in terms of DFS or OS prediction, again 
revealing this signature to be prognostic yet not predictive. 
DISCUSSION
We hereby report that the expression of two crucial 
DNA repair proteins, MSH2 and BRCA1, in early-stage 
NSCLC samples from patients who received preoperative 
platinum-based doublets in a Phase 3 trial, defines three 
distinct groups of high, intermediate, and low risk of 
death, according to their respective tumor expression of 
MSH2 and BRCA1. 
Though the role of MSH2 is well established in 
several cancers, especially hereditary nonpolyposis 
colon cancer, with tumor immunohistochemistry used as 
a reliable tool for HNPCC its involvement in NSCLC is 
not yet clearly defined, with no report of any MSH2 gene 
mutations in such cancer subtype [35,36]. Kamal et al. 
studied MSH2 protein expression using IHC in 673 tumor 
tissue paraffin-embedded samples from patients with 
resected NSCLC who received adjuvant platinum-based 
chemotherapy, reporting that MSH2 protein expression 
was a predictive factor [16]. In their work, high MSH2 
expression was less frequent than in ours (38% vs. 53.1%, 
respectively), although different methods were used 
(high expression defined as a staining intensity >2, while 
we used a composite score). Patients with high MSH2 
expression had an OS of 42 months (vs. 58 months for 
the others). In the current bio-IFCT-0002 study, patients 
with high MSH2 expression have an OS of 60 months 
(vs. over 100 months for the others). Several differences 
between these two studies must be emphasized: i) the 
sample size (356 vs. 673 for Kamal’s study), ii) the 
patients’ treatments (carboplatin/paclitaxel or cisplatin/
gemcitabine combination in the IFCT-0002 trial, cisplatin-
based adjuvant chemotherapy with a large percentage of 
older second-generation drugs in the IALT trial), iii) the 
chemotherapy administration schedule (patients in the 
IFCT-0002 trial received neo-adjuvant chemotherapy and 
tissue block samples were extracted during surgery, while 
IALT trial patients only received adjuvant chemotherapy). 
Nevertheless, our findings are in line with those of 
Kamal’s study: high MSH2 expression is a very strong 
prognostic factor. 
We also report that using an additional marker may 
provide a better prognostic evaluation. Several DNA 
repair proteins could be used as prognostic or predictive 
biomarkers of response to chemotherapy or radiation in 
lung cancer patients. Kamal et al., for example, reported 
that combining both MSH2 and ERCC1 markers achieved 
better prediction of long-term chemotherapy benefit 
than using either one alone [16]. However, the ERCC1 
monoclonal 8F1 antibody was disqualified in a more 
recent report from the same team due to specificity issues 
[37].
In the Bio-IFCT0002 study, high MSH2 expression 
combined with low BRCA1 expression indicated a 
risk of recurrence and death in early-stage lung cancer 
patients treated with perioperative chemotherapy. 
BRCA1 gene expression could be affected by allelic 
loss, gene mutations altering mRNA stability or promoter 
hypermethylation. We were not able to directly assess the 
influence of chemotherapy on tumor BRCA1 expression, 
but the lack of BRCA1 mRNA increase in bronchial 
cells or lung cancer cell lines on chemotherapy exposure 
indicates that neo-adjuvant chemotherapy had no influence 
on BRCA1 content in our patients, and that such treatment 
cannot account for the prognostic discrepancies with 
previously published papers. Indeed, in contrast to our 
findings, low BRCA1 expression was previously reported 
to be a potential biomarker for predicting the benefit 
of perioperative cisplatin-based chemotherapy [38]. 
Furthermore, high BRCA1 mRNA levels correlated with 
shorter OS in another study on chemo-naive patients with 
resected NSCLC [13]. All these findings were generated by 
means of mRNA analyses differing from ours using IHC 
analysis of protein expression. Other striking differences 
between our study and the literature are the proportion 
of squamous-cell carcinomas (SCC). SCC accounted for 
36.5% of patients in the Bio-IFCT0002 trial versus 47% 
in the Taron study and 74% in the Rosell study [13,38]. 
Moreover, Rosell reported a significantly higher content 
of BRCA1 mRNA in SCCs than in adenocarcinomas. Both 
of these studies also included Stage III patients (17.5% 
and 81%, respectively), rendering any comparison with 
the Bio-IFCT 0002 dataset challenging. The largest dataset 
of BRCA1 and MSH2 IHC (769 samples) was derived 
from the IALT adjuvant study [39]. which used tissue 
microarrays (TMAs) and digital-based automated scoring. 
In this series, comprising 57% SCC patients, BRCA1 
expression was below the median expression score value 
in 65% of patients, vs. 41% in our series, suggesting 
significant differences in IHC scoring between the studies. 
It could, alternatively, indicate discrepancies in the 
influence of SCC proportion (57%), since the IALT study 
also reported higher BRCA1 expression in SCC samples. 
In their large patient sample, neither MSH2 nor BRCA1 
were found to significantly influence OS, either in SCC or 
in the whole group, despite MSH2 expression being found 
to significantly predict DFS in SCC patients, though not 
in the whole population. These results contrast with those 
of earlier studies by the Rosell group (analyzing BRCA1 
mRNA expression), thus suggesting the importance of 
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epigenetic BRCA1 expression. The authors also contradict 
their own previously-published data (analyzing MSH2 
IHC), suggesting the influence of TMA sampling biases, 
as compared with whole tumor section analysis [16] or 
suggesting some versatility of DNA-repair markers.
Whether combining MSH2 and BRCA1 markers 
could override conflicting data from the literature still 
requires confirmation in a prospective independent 
homogenous series of early-stage patients, as such 
discrepancies often result from differences in methodology 
and populations. However, this combination could create 
a more powerful prognostic model, as shown by the re-
sampling internal validation of our MSH2/BRCA1 dual 
signature.
Our data thus demonstrate that specific biomarkers 
for DNA repair pathways can provide important 
prognostic information. Whether such information can 
guide oncologists in therapeutic decisions requires further 
prospective validation and the MSH2/BRCA1 signature 
deserves validation in patients included in the future neo-
adjuvant clinical trials. The pharmacological modulation 
of DNA repair proteins has been suggested to increase 
the efficacy of DNA-interacting chemotherapy and 
radiotherapy, favoring tumor cell death primed by single- 
or double-strand DNA breaks [43]. Our data also provide a 
rationale to assess whether Poly(ADP-ribose) polymerase 
(PARP) inhibitors would increase chemotherapy efficacy 
in lung cancer patients with abnormal MSH2 or BRCA1 
content, by a synthetic lethality mechanism.
MATERIALS AND METHODS
Patients and the Bio-IFCT 0002 trial
Between 2001 and 2005, the IFCT 0002 Phase 3 
trial accrued 528 patients [5], comparing two platinum-
based perioperative chemotherapy regimens, gemcitabine 
plus cisplatin or paclitaxel plus carboplatin, in Stage I or II 
NSCLC patients. Specific informed consent was obtained 
for biological studies (Bio-IFCT 0002) and approved 
by the trial’s appointed ethics committee (CPPRB of 
the Besançon University Hospital, France). Diagnostic 
biopsy samples before surgery were not available for 
comparison with post-operative samples used in this study 
since obtained by bronchial endoscopy and CT-guided 
trans-thoracic fine-needle aspiration biopsy, thus small-
sized and used for routine histological characterization 
by standard immunohistochemistry (TTF1, p40, CK7, 
CK20 immunohistochemistry and HES, PAS-diastase 
colorations). 
Immunohistochemistry (IHC) and scoring
Paraffin-embedded surgical blocks were collected 
from 491 patients with incomplete histological response 
following neo-adjuvant chemotherapy. In this series, 7.2% 
of patients had complete histological response and only 
461/528 (87%) specimens were available for IHC analysis 
[25]. Tumor paraffin-embedded blocks were processed 
as previously described [25]. Slides were incubated 
with primary antibody against BRCA1 (AbCam, clone 
8F7, 1/400 - 20 min RT), MSH2 (Calbiochem, clone 
FE11, 1/200 - 60 min RT), or XRCC5 (Genetex, clone 
S10B1, 1/900 - 30 min RT), then revealed using the 
Novolink (Menarini, for BRCA1, MSH2) or Envision 
(Dako, for XRCC5) kits. Positive internal controls were 
systematically evaluated (normal epithelial cells). All 
slides were examined by one of four expert thoracic 
pathologists depending on the protein under analysis, 
one molecular biologist, and one clinician, all blinded 
to individual patient data. The staining intensity of each 
tumor-cell cluster, scored as 0 (negative), 1 (weak), 2 
(moderate), or 3 (strong), at 40x magnification, was 
established by consensus among the three analysts 
(representative examples shown in Figure 1). The same 
overall IHC score was calculated for each staining by 
taking the sum of the staining intensity (0-3) multiplied 
by the distribution (0-100%), giving an H score between 
0 and 300.
O6MGMT promoter hypermethylation assay
Snap-frozen specimens were collected in centers 
possessing the facilities to bank frozen tissues at 
-80°C. The DNA yield from 208 samples was sufficient 
for independent polymerase chain reaction (PCR) 
amplifications for multiple molecular analyses, as 
previously published [26]. O6MGMT hypermethylation 
promoter was assayed by methylation-specific PCR 
(MS-PCR), with genomic DNA bisulfite modification 
performed using the Epitect™ kit (Qiagen, France), and 
PCR amplification as reported by Esteller et al. [41] PCR 
products were loaded onto 5% agarose gels, stained with 
Gel-Red™ (Interchim, France) and visualized under UV 
light.
Cell culture and treatments
Isogenic immortalized human bronchial epithelial 
cells (HBEC) HBEC-3 and HBEC-3-RasG12V bronchial 
cells (42] were grown in KFSM (keratinocyte serum-free 
medium) supplemented with EGFr (0.2ng/ml) and BPE 
(bovine pituitary extracts, 25µg/ml) at 37°C in 5% CO2. 
The tumorigenic epithelial lung cancer-derived cells 
H1299, H1650, H1975, and A549 were from the American 
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Type Culture Collection and used in early passages after 
reception. At 50% confluence, the cells were incubated or 
not for 1h with a p38 inhibitor, SB202190 (20µM), then 
cisplatin (2µM) was added for 3h before 48h of incubation 
with gemcitabine (250nM) or paclitaxel (10nM).
DNAfragmentation 
DNA fragmentation was assayed following the 
manufacturer’s procedures (Cell Death Detection ELISA 
plus kit™; Roche), with the cytoplasmic cell fraction used 
in the enzyme-linked immunosorbent assay, and 405nm 
optical density (OD, absorbance) was determined using 
a micro-plate reader following 5-min incubation with 
peroxidase substrate.
Reverse transcription-quantitative real-time-PCR 
(RT-PCR)
Following extraction, RT-PCR was performed with 
each primer set (Table 3), as previously described [25]. 
RT-PCR data was normalized to the human S16. Relative 
quantification was calculated using the delta-deltaCt 
method.
Immunoblotting
The antibodies used for IHC were the same as those 
used for WB. Whole-cell protein extracts were analyzed 
by WB, as previously described [25], with proteins 
detected with an enhanced chemiluminescence technique 
using the ECL kit™ (Promega). 
Immunofluorescence and image analysis
We performed immunofluorescence studies using 
the cytochrome C primary antibody from BD Biosciences 
diluted in 1% bovine serum albumin (BSA)/phosphate 
buffered saline (PBS) containing 0.3% triton X-100, 
added overnight at 1/50 and 4°C. The Alexa Fluor 555 
(Invitrogen) secondary antibody was added for 1h at room 
temperature in 1% BSA/PBS. Coverslips were mounted 
with DAPI (Santa CruzTM) and image captured with 
high-throughput confocal microscopy (FluoView FV1000, 
Olympus™). 
Statistical analysis
The Bio-IFCT0002 study was a pre-planned 
ancillary and exploratory study. The characteristics of 
patients positive or not for each DNA repair protein on 
IHC, or exhibiting molecular alterations, were compared 
using chi-squared tests or Fisher’s exact tests for 
qualitative variables, and Student’s t-tests for quantitative 
variables. Associations between DNA repair protein 
expression and clinical characteristics were evaluated 
using chi-squared tests, Fisher’s exact tests, or Student’s 
t-tests. 
Prognosis values for disease-free survival (DFS) 
and overall survival (OS), based on IHC scores, were 
assessed using Cox models. Interaction tests were used to 
evaluate predictive values. IHC scores were first studied 
as continuous variables ranging from 0 to 300. Median 
follow-up was estimated using the reverse Kaplan-Meier 
method. Multivariate Cox models were used to adjust for 
patients’ characteristics associated with the corresponding 
outcomes (DFS or OS) at p <0.20 in univariate analysis. 
In all models, the IHC scores were dichotomized 
(negative/positive) as indicated by a fractional polynomial 
analysis, the median value being selected in both MSH1 
and BRCA1 analyses by this methodology. A two-
step bootstrap re-sampling analysis was performed to 
validate the prognostic model, testing its stability and 
reproducibility [43] .The data was analyzed with SPSS 
software SPSS for Windows Version 15.0, Chicago, IL: 
SPSS, Inc., 2006), the mfp package of R software (mfp: 
multivariable fractional polynomials, R package Version 
1.4.0, original by Gareth Ambler and modified by Axel 
Benner, 2007) and SAS software, Version 9.3 (SAS 
Institute Inc., Cary, NC, USA). The in vitro data are 
presented as mean ± standard error of the mean (SEM) of 
the three independent experiments. Statistical differences 
were assessed by Student’s paired t-test for single 
comparisons or one-way analysis of variance (ANOVA), 
followed by Dunnett’s multiple comparison test, to 
compare each condition from a given experiment with a 
single control (siNeg) (GraphPad Software, Inc. USA). 
Statistical significance was set at p ≤0.05.
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